Cardiovasc plus®

A unique formulation of 10 active ingredients for the treatment of cardiovascular and cerebrovascular diseases.

The effect on the cardiovascular system:

  • reduces atherosclerotic plaques
  • reduces the risk of cardiovascular events and mortality

Regulates the level of blood lipids and sugar

  • ↓ LDL,↑ HDL, ↓triglycerides

The effect on the central nervous system:

  • reduces the risk of cerebrovascular events and mortality
  • improves memory and remembering ability
  1. Omega-3 from krill oil:
  • high bioavailability
  • lowers triglycerides by 11%
  • lowers cholesterol by 13%
  • lowers LDL by 32%
  • increases HDL by 44%
  • without unpleasant smell and taste
  1. Phospholipids
  2. Astaxanthin is a potent antioxidant (approximately 500 times stronger than vitamin C and vitamin E)
  3. Q10 of natural origin
  • It is recommended as a supplement to statins and betablockers that lead to a deficit in coenzyme Q10 – lower probability of muscle fatigue
  • It is recommended to patients with cardiomyopathy and heart failure
  1. Magnesium contributes to electrolytic balance, energy generation, and nervous system functioning
  2. Iron
  3. Vitamin B6
  1. Vitamin B12

  • contribute to the creation of red blood cells

  • contribute to the normal functioning of the immune system

  • contribute to energy generation and play a significant role in cell division

  1. Selenium protects cells from oxidative stress and contributes to strengthening of the immune system

  2. Zinc contributes to the DNA creation, fatty acid metabolism, and it protects cells from oxidative stress 

Krill oil – superior antioxidative activity!

54 times stronger antioxidant than fish oils

 

Oxygen Radical Absorbtion Capacity

ASTAXANTIN

A powerful antioxidant that penetrates blood-brain barrier and, in that manner, exerts antioxidative properties on the brain tissue as well.

It has a beneficial impact on:

  • Cerebrovascular ischemia
  • Ischemic heart disease
  • Atherosclerosis
  • Anti-inflammatory effect

(regulation of the production of NO, TNF, and PGE2 and the inhibition of NF-kb and IL-1b)

 

In the experimental model, the overall surface of the ischemic

lesion was reduced by 40% in the group treated with ASTAXANTHIN

CardioVasc Plus-Omega 3
conclusions of studies and recommendations:

Maximum effect in the first months after myocardial infarction (IM) – a considerable early effect on overall mortality in the first 3 months upon IM and on sudden heart mortality after 4 months.

Its supplementation to statins reduces the risk of significant coronary events by 19%. Positive effect on heart and the process of atherosclerosis:

↓Malignant ventricular arrhythmias (stabilization of the myocyte membrane)

↓Heart rate

↑ Endothelial relaxing (through ↑NO &↑NO independent mechanisms)

↓Blood pressure

↓Sudden cardiac death

↓Overall and CVD mortality

Anti-proliferative effect (↓proliferation of smooth muscle cells)

Antithrombotic effect (↓ platelet reactivity, ↓anti-coagulation)

Anti-inflammatory effects (↓Inflammatory cytokines, ↓Mitogens, ↓Expression of adhesion molecules)

CardioVasc Plus

administration:

  • patients with severe lipid disorder

  • patients on statin or betablocker therapy (+ Q10)

  • patients with myocardiopathy and/or heart failure (+ Q10)

  • Alternative for statin therapy

At the primary prevention with hypercholesterolemia patients
At monotherapy (a patient does not need to use statin or delays the administration of statin)

  • Three months of dieting and supplementation and with high-risk patients – drugs are not immediately introduced

  • Achieving target values – the need for introducing statin is excluded – there is no fear of adverse effects of statin

  • It is in guidelines: National Guide on Lipid Disorders

In the combination therapy with statins – if previously CardioVasc and dieting fail to achieve target values 
In secondary CVD prevention – statin + CardioVasc Plus
Additive effect in the combination therapy with statins for the reduction of CVD disorders and lipid correction

  • administration of lower dosages of statin – lower risk of the occurrence of side effects of statin

  • Higher safety in comparison to fibrates in the combination therapy with statins

Instead of statin with patients that do not tolerate it or do not want to take it

Lipid status disorder

  • The increase of the cholesterol level by 2-3% increases the risk of ischemic heart disease by 1%,

  • The reduction of the level of LDL cholesterol can reduce morbidity and mortality by 40%,

  • The increase of the HDL level by 1mg/dl reduces the risk of cardio-vascular diseases by 2-3%,

  • The rise in the triglyceride levels (TCG) is an independent risk factor for the occurrence of cardio-vascular diseases

  • Preferred values of lipid fractions for general population:

Target values of LDL cholesterol depending on the level of risk – European recommendations:

 

Limiting effect of statin usage:

 

  • Statins have limited effect on ↓TCG and ↑HDL!
  • After the statin therapy, there is still a significant cardio-vascular risk
  • Side effects of statin are frequent and serious (FDA warning): diabetes, CNS (confusion and forgetfulness), hepatotoxicity, rhabdomyolysis, myalgia, muscle cramps
  • There is a large number of statin interactions with fibrates, anticoagulants, digoxin, and other inhibitors of cytochrome P450!

CardioVasc Plus

administration:

  • patients with severe lipid disorder

  • patients on statin or betablocker therapy (+ Q10)

  • patients with myocardiopathy and/or heart failure (+ Q10)

  • Alternative for statin therapy

At the primary prevention with hypercholesterolemia patients
At monotherapy (a patient does not need to use statin or delays the administration of statin)

  • Three months of dieting and supplementation and with high-risk patients – drugs are not immediately introduced

  • Achieving target values – the need for introducing statin is excluded – there is no fear of adverse effects of statin

  • It is in guidelines: National Guide on Lipid Disorders

In the combination therapy with statins – if previously CardioVasc and dieting fail to achieve target values 
In secondary CVD prevention – statin + CardioVasc Plus
Additive effect in the combination therapy with statins for the reduction of CVD disorders and lipid correction

  • administration of lower dosages of statin – lower risk of the occurrence of side effects of statin

  • Higher safety in comparison to fibrates in the combination therapy with statins

Instead of statin with patients that do not tolerate it or do not want to take it

Lipid status disorder

  • The increase of the cholesterol level by 2-3% increases the risk of ischemic heart disease by 1%,

  • The reduction of the level of LDL cholesterol can reduce morbidity and mortality by 40%,

  • The increase of the HDL level by 1mg/dl reduces the risk of cardio-vascular diseases by 2-3%,

  • The rise in the triglyceride levels (TCG) is an independent risk factor for the occurrence of cardio-vascular diseases

  • Preferred values of lipid fractions for general population:

Target values of LDL cholesterol depending on the level of risk – European recommendations:

 

Limiting effect of statin usage:

 

  • Statins have limited effect on ↓TCG and ↑HDL!
  • After the statin therapy, there is still a significant cardio-vascular risk
  • Side effects of statin are frequent and serious (FDA warning): diabetes, CNS (confusion and forgetfulness), hepatotoxicity, rhabdomyolysis, myalgia, muscle cramps
  • There is a large number of statin interactions with fibrates, anticoagulants, digoxin, and other inhibitors of cytochrome P450!

Write to us

6 + 7 =

Mosorska 9, 11000 Belgrade, Serbia

Vemax011 Pharma doo representative office Northern Macedonia - Dane Krapcev 13, Skopje

Vemax011 Pharma doo representative office Montenegro - Topliški put 1, Budva

Vemax011 Pharma doo representative office Bosnia and Hercegovina - Vlakovo 252, Sarajevo

+381 (0)69 801 47 87

office@vemaxpharma.rs

Vemax Pharma - your trusted regional partner on the road to health!